{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:34:21Z","timestamp":1778222061004,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,3,24]],"date-time":"2009-03-24T00:00:00Z","timestamp":1237852800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Prostate Cancer (PCa) is the second most frequent neoplasia in men worldwide. Previous reports suggest that the prevalence of PCa in Hispanic males is lower than in Africans (including communities with African ancestry) and Caucasians, but higher than in Asians. Despite these antecedents, there are few reports of open population screenings for PCa in Latin American communities. This article describes the results of three consecutive screenings in the urban population of Monterrey, Mexico.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>After receiving approval from our University Hospital's Internal Review Board (IRB), the screening was announced by radio, television, and press, and it was addressed to male subjects over 40 years old in general. Subjects who consented to participate were evaluated at the primary care clinics of the University Health Program at UANL, in the Metropolitan area of Monterrey. Blood samples were taken from each subject for prostate specific antigen (PSA) determination; they underwent a digital rectal examination (DRE), and were subsequently interviewed to obtain demographic and urologic data. Based on the PSA (&gt;4.0 ng\/ml) and DRE results, subjects were appointed for transrectal biopsy (TRB).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 973 subjects were screened. Prostate biopsy was recommended to 125 men based on PSA values and DRE results, but it was performed in only 55 of them. 15 of these biopsied men were diagnosed with PCa, mostly with Gleason scores \u2265 7.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our results reflect a low prevalence of PCa in general, but a high occurrence of high grade lesions (Gleason \u2265 7) among patients that resulted positive for PCa. This observation remarks the importance of the PCa screening programs in our Mexican community and the need for strict follow-up campaigns.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-9-91","type":"journal-article","created":{"date-parts":[[2009,3,24]],"date-time":"2009-03-24T19:13:37Z","timestamp":1237922017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Population based prostate cancer screening in north Mexico reveals a high prevalence of aggressive tumors in detected cases"],"prefix":"10.1186","volume":"9","author":[{"given":"Lauro S","family":"Gomez-Guerra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita L","family":"Martinez-Fierro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Alcantara-Aragon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocio","family":"Ortiz-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca T","family":"Martinez-Villarreal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idelma B","family":"Morales-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Garza-Guajardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco A","family":"Ponce-Camacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto","family":"Rojas-Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,24]]},"reference":[{"key":"1425_CR1","unstructured":"Sistema Nacional de Informaci\u00f3n en Salud: Base de datos 2005. [http:\/\/sinais.salud.gob.mx\/mortalidad\/]"},{"key":"1425_CR2","unstructured":"Programa de Acci\u00f3n: C\u00e1ncer de Pr\u00f3stata. Centro Nacional de Vigilancia Epidemiol\u00f3gica. Secretar\u00eda de Salud de M\u00e9xico. 2001, [http:\/\/bibliotecas.salud.gob.mx\/gsdl\/collect\/publin1\/index\/assoc\/HASH18a3.dir\/doc.pdf]"},{"issue":"11","key":"1425_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.7326\/0003-4819-137-11-200212030-00014","volume":"137","author":"R Harris","year":"2002","unstructured":"Harris R, Lohr KN: Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002, 137 (11): 917-929.","journal-title":"Ann Intern Med"},{"issue":"10","key":"1425_CR4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jama.1994.03520100035030","volume":"272","author":"MD Krahn","year":"1994","unstructured":"Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS: Screening for prostate cancer. A decision analytic view. JAMA. 1994, 272 (10): 773-780. 10.1001\/jama.272.10.773.","journal-title":"JAMA"},{"issue":"9","key":"1425_CR5","doi-asserted-by":"publisher","first-page":"914","DOI":"10.7326\/0003-4819-119-9-199311010-00009","volume":"119","author":"BS Kramer","year":"1993","unstructured":"Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK: Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993, 119 (9): 914-923.","journal-title":"Ann Intern Med"},{"key":"1425_CR6","unstructured":"Society AC: Detailed guide: Prostate cancer. [http:\/\/www.cancer.org\/docroot\/CRI\/content\/CRI_2_4_3X_Can_prostate_cancer_be_found_early_36.asp]"},{"key":"1425_CR7","doi-asserted-by":"crossref","unstructured":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008, 149 (3): 185-191. 2008\/08\/06 edition","DOI":"10.7326\/0003-4819-149-3-200808050-00008"},{"issue":"15","key":"1425_CR8","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/jnci\/93.15.1153","volume":"93","author":"RF Hoedemaeker","year":"2001","unstructured":"Hoedemaeker RF, Kwast van der TH, Boer R, de Koning HJ, Roobol M, Vis AN, Schroder FH: Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst. 2001, 93 (15): 1153-1158. 10.1093\/jnci\/93.15.1153.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1425_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.urology.2003.09.083","volume":"63","author":"MJ Roobol","year":"2004","unstructured":"Roobol MJ, Kranse R, de Koning HJ, Schroder FH: Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology. 2004, 63 (2): 309-313. 10.1016\/j.urology.2003.09.083. discussion 313\u2013305.","journal-title":"Urology"},{"issue":"22","key":"1425_CR10","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1056\/NEJMoa031918","volume":"350","author":"IM Thompson","year":"2004","unstructured":"Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004, 350 (22): 2239-2246. 10.1056\/NEJMoa031918.","journal-title":"N Engl J Med"},{"issue":"2","key":"1425_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1080\/00365590510007685","volume":"39","author":"H Hedelin","year":"2005","unstructured":"Hedelin H, Johansson N, Stroberg P: Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate-specific antigen in clinical routine. Scand J Urol Nephrol. 2005, 39 (2): 154-159. 10.1080\/00365590510007685.","journal-title":"Scand J Urol Nephrol"},{"issue":"6","key":"1425_CR12","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.urology.2004.08.060","volume":"64","author":"LH Simardi","year":"2004","unstructured":"Simardi LH, Tobias-MacHado M, Kappaz GT, Taschner Goldenstein P, Potts JM, Wroclawski ER: Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study. Urology. 2004, 64 (6): 1098-1101. 10.1016\/j.urology.2004.08.060.","journal-title":"Urology"},{"issue":"2","key":"1425_CR13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0022-5347(01)63946-6","volume":"159","author":"J Pannek","year":"1998","unstructured":"Pannek J, Marks LS, Pearson JD, Rittenhouse HG, Chan DW, Shery ED, Gormley GJ, Subong EN, Kelley CA, Stoner E, et al: Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol. 1998, 159 (2): 449-453. 10.1016\/S0022-5347(01)63946-6.","journal-title":"J Urol"},{"issue":"1","key":"1425_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0022-5347(01)65322-9","volume":"157","author":"LA Eskew","year":"1997","unstructured":"Eskew LA, Bare RL, McCullough DL: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 1997, 157 (1): 199-202. 10.1016\/S0022-5347(01)65322-9. discussion 202-193.","journal-title":"J Urol"},{"issue":"1","key":"1425_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000020102","volume":"37","author":"C Brossner","year":"2000","unstructured":"Brossner C, Madersbacher S, Bayer G, Pycha A, Klingler HC, Maier U: Comparative study of two different TRUS-guided sextant biopsy techniques in detecting prostate cancer in one biopsy session. Eur Urol. 2000, 37 (1): 65-71. 10.1159\/000020102.","journal-title":"Eur Urol"},{"issue":"4","key":"1425_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1159\/000100834","volume":"78","author":"K Stamatiou","year":"2007","unstructured":"Stamatiou K, Alevizos A, Karanasiou V, Mariolis A, Mihas C, Papathanasiou M, Bovis K, Sofras F: Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer. Urol Int. 2007, 78 (4): 313-317. 10.1159\/000100834.","journal-title":"Urol Int"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-91.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-9-91\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-91","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-91.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:18:28Z","timestamp":1630462708000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-9-91"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,24]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1425"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-9-91","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,24]]},"assertion":[{"value":"22 August 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"91"}}